
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































The kit is developed for quantitative detection of natural and recombinant mouse IL-6 in serum, plasma and cell culture supernatants.
It is for research use only.

| Assay Type | Sandwich-ELISA |
| Analyte | Mouse IL-6 |
| Format | 96-wells plate breakable into 12 x 8 wells strips |
| Reactivity | Mouse |
| Sensitivity | 10 pg/mL |
| Assay Time | 2.75 hr |
| Sample volume | 50 μL |
| Range | 18.75 pg/mL-600 pg/mL |
| Sample Type | For the quantitative determination of mouse IL-6 in serum, plasma and cell supernatant. |
| NIBSC Code | 93/730, NIBSC/WHO (93/730) approximate value (U/mL) = 0.25 x ACRO Mouse IL-6 (pg/mL) |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was cal-culated based on the results of the standard curve. The minimum detectable con-centration of mouse IL-6 is less than 10 pg/mL.
Serum Sample: The mice in the experimental group were injected with 15 μg or 30 μg of LPS and bled 4 hours after injection. In contrast, those in the control group received an equivalent volume of normal saline (NS). Serum samples were collected from all mice, and IL-6 concentrations were quantitatively measured using standardized immunoassays.

Ten replicates of each of three samples containing different Mouse IL-6 concen-trations were tested in one assay. Acceptable criteria: CV<10%.

Three samples containing different concentrations of Mouse IL-6 were tested in independent assays. Acceptable criteria: CV<15%.

Recombinant IL-6 was spiked into three mouse serum samples, and then analyzed. The average recovery of IL-6 for serum samples is 88.7%.

| ID | Components | Size |
| CEA254-C01 | Pre-coated Anti-mouse-IL-6 Antibody Microplate | 1 plate |
| CEA254-C02 | Mouse IL-6 Standard | 6 ng×2 |
| CEA254-C03 | Biotin-Anti-mouse-IL-6 Antibody Con. Solution | 100 μL |
| CEA254-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
| CEA254-C05 | Streptavidin-HRP Con. Solution | 500 μL |
| CEA254-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
| CEA254-C07 | 20×Washing Buffer | 50 mL |
| CEA254-C08 | Sample Dilution Buffer | 15 mL×2 |
| CEA254-C09 | Substrate Solution | 12 mL |
| CEA254-C10 | Stop Solution | 6 mL |
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Immune System Diseases; Psoriasis | Details | ||
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | Mainland China | Multicentric Castleman's Disease (MCD) | Beigene (Beijing) Biotechnology Co Ltd | 2014-04-23 | Immunoglobulin Light-chain Amyloidosis; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lung Neoplasms; Primary Myelofibrosis; Colorectal Neoplasms; Castleman Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Kidney Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Psychotic Disorders; Polycythemia Vera; Carcinoma, Renal Cell; Schizophrenia; Diabetes Mellitus, Type 1; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Bone Marrow Neoplasms | Details |
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | Mainland China | Multiple Myeloma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2013-02-08 | Pulmonary Fibrosis; Anemia, Sickle Cell; Atypical Squamous Cells of the Cervix; Neurofibromatosis 1; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Glioma; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Sarcoma; Prostatic Neoplasms; Thrombocytosis; Lung Diseases, Interstitial; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Scleroderma, Systemic; Pancreatic Neoplasms; Kidney Diseases; Immunoglobulin Light-chain Amyloidosis; Graft vs Host Disease; Myeloproliferative Disorders; Plasmacytoma; Polycythemia Vera; Medulloblastoma; Bone Marrow Neoplasms | Details |
| Lenalidomide | CC-5013; IMiD-3; ENMD-0997; STAR-LLD; CDC-501; IMID-5013; CDC-5013 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | EU | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular | Celgene Europe Bv | 2005-12-27 | Leukemia; Leukemia, Myeloid; Immunoproliferative Small Intestinal Disease; Leukemia, Erythroblastic, Acute; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Medulloblastoma; Intestinal Neoplasms; Bone Marrow Neoplasms; Solid tumours; Kidney Neoplasms; Liver Neoplasms; HIV Infections; Hematologic Diseases; Optic Nerve Glioma; Leukemia, Promyelocytic, Acute; Ependymoma; Anemia, Refractory, with Excess of Blasts; Plaque, Amyloid; Leukemia, Hairy Cell; Anemia; Paraproteinemias; Pain; Polycythemia Vera; Rhabdoid Tumor; Hodgkin Disease; Myelodysplastic Syndromes; Nerve Degeneration; Lymphomatoid Granulomatosis; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Anemia, Refractory; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Lymphoma, Large B-Cell, Diffuse; Blood Protein Disorders; Neoplasms; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Hypothalamic Neoplasms; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Acute; Urinary Bladder Neoplasms; Multi | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| Wogonin | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Respiratory Tract Infections; Neoplasms | Details | |
| Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | Prometic Life Sciences | Details | ||
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| PF-04236921 | PF-4236921; PF-04236921 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| Olokizumab | CDP-6038; Anti-IL6-UCB | Ucb | Details | ||
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Cicatrix | Details |
| FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Janssen Global Services Llc | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lupus Erythematosus, Cutaneous; Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
| Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Swiss Biopharma Med GmbH | Pyoderma Gangrenosum; Pyoderma | Details | |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Solid tumours; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis; Kidney Failure, Chronic | Details |
| RO-7200220 | RO-7200220 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Diabetic macular oedema | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Pharmaceutical Co Ltd | Heart Failure; Anemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation; Systemic Inflammatory Response Syndrome | Details |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.




